CR20160115A - Polipéptidos de factor de crecimiento de tipo insulina estabilizada - Google Patents

Polipéptidos de factor de crecimiento de tipo insulina estabilizada

Info

Publication number
CR20160115A
CR20160115A CR20160115A CR20160115A CR20160115A CR 20160115 A CR20160115 A CR 20160115A CR 20160115 A CR20160115 A CR 20160115A CR 20160115 A CR20160115 A CR 20160115A CR 20160115 A CR20160115 A CR 20160115A
Authority
CR
Costa Rica
Prior art keywords
growth factor
type growth
factor polypeptides
insulin type
stabilized insulin
Prior art date
Application number
CR20160115A
Other languages
English (en)
Inventor
David Jonathan Glass
Mara Fornaro
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38801859&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CR20160115(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of CR20160115A publication Critical patent/CR20160115A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/30—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/65—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Ophthalmology & Optometry (AREA)
  • Dermatology (AREA)
  • Obesity (AREA)
  • Pulmonology (AREA)

Abstract

La invención se refiere a polipéptidos estabilizados que tienen una secuencia de IGF-1 o IGF-2 y una secuencia de péptido E, en donde la escisión fisiológica natulal del péptido E a partir de IGF es evitada.
CR20160115A 2006-06-09 2016-03-07 Polipéptidos de factor de crecimiento de tipo insulina estabilizada CR20160115A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US81234906P 2006-06-09 2006-06-09
US86224406P 2006-10-20 2006-10-20
US89718707P 2007-01-24 2007-01-24
PCT/US2007/070468 WO2007146689A2 (en) 2006-06-09 2007-06-06 Stabilized insulin-like growth factor polypeptides

Publications (1)

Publication Number Publication Date
CR20160115A true CR20160115A (es) 2016-06-14

Family

ID=38801859

Family Applications (2)

Application Number Title Priority Date Filing Date
CR10432A CR10432A (es) 2006-06-09 2008-11-10 Polipeptidos de factor de crecimiento de tipo insulina estabilizada
CR20160115A CR20160115A (es) 2006-06-09 2016-03-07 Polipéptidos de factor de crecimiento de tipo insulina estabilizada

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CR10432A CR10432A (es) 2006-06-09 2008-11-10 Polipeptidos de factor de crecimiento de tipo insulina estabilizada

Country Status (33)

Country Link
US (4) US8343918B2 (es)
EP (2) EP2032155B1 (es)
JP (2) JP5290966B2 (es)
KR (1) KR101459789B1 (es)
AR (1) AR061242A1 (es)
AU (2) AU2007257936B2 (es)
BR (2) BRPI0712052A2 (es)
CA (2) CA2653781A1 (es)
CL (1) CL2007001614A1 (es)
CR (2) CR10432A (es)
CY (1) CY1116117T1 (es)
DK (2) DK2032155T3 (es)
EC (1) ECSP088949A (es)
ES (1) ES2529261T3 (es)
GT (1) GT200800273A (es)
HK (1) HK1126429A1 (es)
HR (1) HRP20150326T1 (es)
IL (1) IL195156A (es)
JO (1) JO2968B1 (es)
MA (1) MA30503B1 (es)
MX (2) MX2008015726A (es)
MY (1) MY147856A (es)
NO (2) NO20085183L (es)
NZ (2) NZ572708A (es)
PE (1) PE20080715A1 (es)
PL (1) PL2032155T3 (es)
PT (1) PT2032155E (es)
RU (1) RU2477287C2 (es)
SI (1) SI2032155T1 (es)
TN (1) TNSN08509A1 (es)
TW (1) TWI427084B (es)
UA (1) UA97953C2 (es)
WO (2) WO2007146689A2 (es)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090318355A1 (en) * 2006-02-15 2009-12-24 Chen Thomas T Compositions and methods for promoting tissue repair and wound healing
AR061242A1 (es) * 2006-06-09 2008-08-13 Novartis Ag Polipeptidos de factor de crecimiento de tipo insulina estabilizada
EP3778652A1 (en) 2008-05-07 2021-02-17 BioMarin Pharmaceutical Inc. Lysosomal targeting peptides and uses thereof
CA2743072A1 (en) * 2008-11-10 2010-05-14 Novartis Ag Antibodies to modified human igf-1/e peptides
US8685403B2 (en) * 2009-01-30 2014-04-01 The Regents Of The University Of California Insulin-like growth factor signaling and integrin
CA2758290C (en) 2009-04-27 2018-04-10 Novartis Ag Antagonistic activin receptor iib (actriib) antibodies for increasing muscle growth
BR112012001363A2 (pt) * 2009-07-22 2016-11-08 Ipsen Pharma Sas análogo de igf-1, composição farmacêutica,e, método para tratar condições ou doenças mediadas pela ligação do receptor de igf-1
WO2011057249A2 (en) * 2009-11-09 2011-05-12 The Brigham And Women's Hospital, Inc. Treatment of heart disease
JP2011160696A (ja) * 2010-02-08 2011-08-25 Novartis Ag 修飾ヒトｉｇｆ−１／ｅペプチドに対する抗体
BR112013020969A2 (pt) 2011-02-23 2018-07-10 Massachusetts Inst Technology proteínas de membrana solúvel em água e métodos para a sua preparação e uso.
US20140357558A1 (en) * 2011-06-24 2014-12-04 Cold Spring Harbor Laboratory Compositions and methods for treatment of spinal muscular atrophy
HUE040276T2 (hu) 2011-07-01 2019-02-28 Novartis Ag Eljárás metabolikus rendellenességek kezelésére
WO2014012025A2 (en) 2012-07-13 2014-01-16 The Trustees Of The University Of Pennsylvania Igf-1 proteins and therapeutic uses thereof
JP6392245B2 (ja) * 2012-12-18 2018-09-19 ノバルティス アーゲー 遺伝子改変哺乳動物細胞における治療用タンパク質の産生
CR20200079A (es) * 2012-12-18 2020-03-21 Novartis Ag POLIPÉPTIDOS ESTABILIZADOS DEL FACTOR DE CRECIMIENTO TIPO INSULINA (Divisional 2015-0324)
AU2014307589A1 (en) 2013-08-14 2016-02-11 Novartis Ag Methods of treating sporadic inclusion body myositis
KR20160091888A (ko) 2013-10-02 2016-08-03 노파르티스 아게 요법에 사용하기 위한 인슐린-유사 성장 인자 모방체
UY35874A (es) * 2013-12-12 2015-07-31 Novartis Ag Un proceso para la preparación de una composición de proteínas pegiladas
WO2015095650A1 (en) * 2013-12-19 2015-06-25 Puretein Bioscience Llc. Methods for treating an animal
WO2015111008A2 (en) 2014-01-27 2015-07-30 Novartis Ag Biomarkers predictive of muscle atrophy, method and use
US10373702B2 (en) 2014-03-27 2019-08-06 Massachusetts Institute Of Technology Water-soluble trans-membrane proteins and methods for the preparation and use thereof
WO2015149085A2 (en) * 2014-03-27 2015-10-01 Massachusetts Institute Of Technology Warer-soluble trans-membrane proteins and methods for the preparation and use thereof
TW201622746A (zh) 2014-04-24 2016-07-01 諾華公司 改善或加速髖部骨折術後身體復原之方法
CN107405387A (zh) * 2015-02-04 2017-11-28 普雷坦生物科技有限责任公司 用于增加后代的性能特性的方法
KR101669140B1 (ko) 2015-04-28 2016-10-26 (주)케어젠 항비만 및 항당뇨 효능을 갖는 펩타이드 및 이의 용도
US11534466B2 (en) 2016-03-09 2022-12-27 Aal Scientifics, Inc. Pancreatic stem cells and uses thereof
KR20240014600A (ko) 2017-03-24 2024-02-01 노바르티스 아게 심장질환 예방 및 치료 방법
JP6691503B2 (ja) * 2017-04-13 2020-04-28 任天堂株式会社 ゲームプログラム、ゲーム処理制御方法、およびゲーム装置
JOP20190245A1 (ar) 2017-04-20 2019-10-15 Novartis Ag أنظمة توصيل إطلاق مستدام تتضمن روابط بلا أثر لنقطة الربط
WO2023145961A1 (ja) * 2022-01-31 2023-08-03 国立大学法人信州大学 ＩＧＦ１Ｒを標的とするｐｒｅ－ｐｒｏ前駆体型キメラ抗原受容体発現細胞

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4980286A (en) * 1985-07-05 1990-12-25 Whitehead Institute For Biomedical Research In vivo introduction and expression of foreign genetic material in epithelial cells
WO1987001038A1 (en) 1985-08-22 1987-02-26 Commonwealth Scientific And Industrial Research Or Peptide analogues of mammalian insulin-like growth factor-1
US5164370A (en) 1987-12-24 1992-11-17 Gropep Pty. Ltd. Peptide analogues of insulin-like growth factor 1 (igf-1) or factor 2 (igf-2)
GB8819826D0 (en) * 1988-08-20 1988-09-21 Kabivitrum Ab Glycosylated igf-1
JPH07508025A (ja) * 1992-05-08 1995-09-07 トーマス・ジェファーソン・ユニバーシティ インスリン様増殖因子（ｉｇｆ−１）類似体
WO1995013290A1 (en) 1993-11-12 1995-05-18 North Shore University Hospital Research Corporation Method of treating muscular dystrophy
WO1995032003A1 (en) 1994-05-24 1995-11-30 Amgen Boulder Inc. Modified insulin-like growth factors
GB9605124D0 (en) * 1996-03-11 1996-05-08 Royal Free Hosp School Med Method of treating muscular disorders
US7118752B2 (en) 1998-07-22 2006-10-10 University Of Connecticut Compositions and methods for inhibiting the proliferation and invasiveness of malignant cells comprising E-domain peptides of IGF-I
DK1141014T3 (da) * 1999-01-06 2005-04-11 Genentech Inc Insulinlignende vækstfaktor (IGF) i mutantvariant
GB9926968D0 (en) * 1999-11-15 2000-01-12 Univ London Treatment of neurological disorders
GB0011278D0 (en) 2000-05-10 2000-06-28 Univ London Repair of nerve damage
JP2005502322A (ja) * 2001-04-19 2005-01-27 ザ スクリップス リサーチ インスティテュート 非天然アミノ酸のインビボ組込み
SE0104140D0 (sv) * 2001-12-07 2001-12-07 Astrazeneca Ab Novel Compounds
GB0202906D0 (en) 2002-02-07 2002-03-27 Univ London Prevention of myocardial damage
EP1576137A4 (en) 2002-10-29 2010-06-30 Genentech Inc COMPOSITIONS AND METHODS FOR TREATING DISEASES RELATED TO THE IMMUNE SYSTEM
WO2005033134A2 (en) * 2003-09-30 2005-04-14 Regeneron Pharmaceuticals, Inc. Secreted protein therapeutics and uses thereof
GB0426154D0 (en) 2004-11-29 2004-12-29 European Molecular Biology Lab Embl IGF-1 novel peptides
EP1674113A1 (en) 2004-12-22 2006-06-28 F. Hoffmann-La Roche Ag Conjugates of insulin-like growth factor-1 (IGF-1) and poly(ethylene glycol)
PT2241575E (pt) * 2005-01-07 2015-09-16 Regeneron Pharma Polipéptidos de fusão que contêm o igf-1 e utilizações terapêuticas desses polipéptidos
WO2006097682A1 (en) 2005-03-18 2006-09-21 Ucl Business Plc Mechano growth factor peptides and their use
WO2006097764A1 (en) 2005-03-18 2006-09-21 Ucl Business Plc Mecano growth factor peptides and their use
WO2006106689A1 (ja) 2005-03-31 2006-10-12 Pioneer Corporation アップグレードモジュール、アプリケーションプログラム、サーバ、及びアップグレードモジュールの配信システム
AR061242A1 (es) 2006-06-09 2008-08-13 Novartis Ag Polipeptidos de factor de crecimiento de tipo insulina estabilizada

Also Published As

Publication number Publication date
BRPI0712147A2 (pt) 2012-02-22
US20140235538A1 (en) 2014-08-21
ECSP088949A (es) 2009-01-30
WO2007146689A2 (en) 2007-12-21
AR061242A1 (es) 2008-08-13
CL2007001614A1 (es) 2008-08-08
BRPI0712052A2 (pt) 2012-01-10
WO2007146689A3 (en) 2008-04-10
AU2007257936B2 (en) 2011-05-26
US8343918B2 (en) 2013-01-01
US20100234290A1 (en) 2010-09-16
CA2654944C (en) 2017-01-03
JO2968B1 (en) 2016-03-15
EP2032154A2 (en) 2009-03-11
CA2653781A1 (en) 2007-12-13
JP2009539805A (ja) 2009-11-19
PL2032155T3 (pl) 2015-05-29
MX2008015657A (es) 2009-02-04
US20170066808A9 (en) 2017-03-09
TWI427084B (zh) 2014-02-21
EP2032155A2 (en) 2009-03-11
CR10432A (es) 2009-01-15
AU2007255419A1 (en) 2007-12-13
NO20085184L (no) 2009-03-03
WO2007146689A9 (en) 2010-12-16
NZ572548A (en) 2011-06-30
JP2009539383A (ja) 2009-11-19
HRP20150326T1 (hr) 2015-04-24
WO2007141309A2 (en) 2007-12-13
PE20080715A1 (es) 2008-07-25
IL195156A0 (en) 2011-08-01
CA2654944A1 (en) 2007-12-21
RU2477287C2 (ru) 2013-03-10
AU2007257936A1 (en) 2007-12-21
MA30503B1 (fr) 2009-06-01
ES2529261T3 (es) 2015-02-18
WO2007141309A3 (en) 2008-05-29
US20100173839A1 (en) 2010-07-08
US8722621B2 (en) 2014-05-13
RU2008151511A (ru) 2010-07-20
NO20085183L (no) 2009-03-09
IL195156A (en) 2014-07-31
DK200900016A (da) 2009-01-06
SI2032155T1 (sl) 2015-04-30
MY147856A (en) 2013-01-31
DK2032155T3 (en) 2015-03-02
HK1126429A1 (en) 2009-09-04
TW200835698A (en) 2008-09-01
NZ572708A (en) 2011-11-25
TNSN08509A1 (en) 2010-04-14
KR20090027197A (ko) 2009-03-16
JP5290966B2 (ja) 2013-09-18
GT200800273A (es) 2009-09-16
CY1116117T1 (el) 2017-02-08
MX2008015726A (es) 2008-12-19
US20130059779A1 (en) 2013-03-07
PT2032155E (pt) 2015-04-07
UA97953C2 (uk) 2012-04-10
EP2032155B1 (en) 2014-12-24
KR101459789B1 (ko) 2014-11-07

Similar Documents

Publication Publication Date Title
CR20160115A (es) Polipéptidos de factor de crecimiento de tipo insulina estabilizada
EA201590525A1 (ru) Слитые белки для лечения метаболического синдрома
PE20121393A1 (es) Analogo peptidico de oxintomodulina
WO2009035540A3 (en) Analogues of exendin-4 and exendin-3
PE20130511A1 (es) Formulaciones de insulina de accion prolongada
CL2012000119A1 (es) Polipeptido f de virus respiratorio sincicial recombinante, composicion inmunogenica que lo comprende, uso para la preparacion de un medicamento para la profilaxis contra dicho virus.
ES2575906T3 (es) Composiciones y métodos de producir metionina
PE20120563A1 (es) Construcciones novedosas de proteina del virus de papiloma humano (hpv) y su uso en la prevencion de la enfermedad por el hpv
AR070690A1 (es) Metodos y composiciones que utilizan polipeptidos de fusion de klotho-fgf (factor de crecimiento de fibroblastos)
BR112012029975A2 (pt) peptídeo como medicamento, em particular para o tratamento do câncer.
AR053803A1 (es) Uso de acido pinolenico
UA118167C2 (uk) Пептид та його застосування
HK1142828A1 (en) Hydrolysable polymeric fmoc-linker
ME01555B (me) FARMACEUTSKI PREPARAT KOJI SADRŽI {lS)-1,5-ANHIDR0-1-[5-{4-ETOKSIBENZIL)-2-METOKSI-4-METILFENIL]-1- TIO-D-GLUCITOL l METFORMIN l NJEGOVE UPOTREBE U LIJEČENJU DIJABETESA
EA200702012A1 (ru) Пептиды механо-фактора роста и их применение
PE20151434A1 (es) Metodos para la reduccion de los riesgos asociados con el insuficiencia cardiaca y factores asociados con el mismo
AR067980A1 (es) Peptidos de cdh3 y agentes que los comprenden
CL2009000190A1 (es) Virus recombinante de la enfermedad de newcastle que comprende un transgen que codifica una citoquina de ave; nucleocapside y genoma de dicho virus; molecula de adn que codifica el genoma y/o antigenoma del virus; celula y composicion que lo comprenden.
PE20191836A1 (es) Compuesto de insulina acilada
AR050887A1 (es) Modificacion del contenido de lignina en plantas
NZ595060A (en) Treatment of cancer with immunostimulatory hiv tat derivative polypeptides
MX2010010177A (es) Fragmentos de beta timosina mejorada.
DE602007009204D1 (de) Von kollagen typ iv abgeleitetes cyclopeptid mit antikrebswirkung
WO2011014680A3 (en) Gastric inhibitory peptide variants and their uses
EA201200889A1 (ru) Пептид